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Abstract
Background: Smoking during pregnancy and in the postnatal period is a major cause of low birth weight and a
range of adverse infant health outcomes. Stop smoking services can double quit rates, but only 17% of pregnant
women smoking at the time they book for antenatal care use these services. In a recent Cochrane review on the
effectiveness of smoking cessation interventions in pregnancy, financial incentives were found to be the single
most effective intervention. We describe a single arm intervention study offering participation in a financial
incentive scheme for smoking cessation to all pregnant smokers receiving antenatal care in one area in England.
The aim of the study is to assess the potential effectiveness of using financial incentives to achieve smoking
cessation in pregnant women who smoke, to inform the use of financial incentive schemes in routine clinical
practice as well as the interpretation of existing trials and the design of future studies.
Method/design: 500 consecutive pregnant smokers are offered participation in the scheme, which involves
attending for up to 32 assessments until six months post-partum, to verify smoking cessation by self report and a
negative exhaled carbon monoxide measurement. At each visit when cessation is verified, participants receive a
shopping voucher starting at a value of £8 and increasing by £1 at each consecutive successful visit. Assessments
decline in frequency, occurring most frequently during the first two weeks after quitting and the first two weeks
after delivery. The maximum cumulative total that can be earned through the scheme is £752.
Discussion: The results of this study will inform the use of financial incentive schemes in routine clinical practice as
well as the interpretation of existing trials and the design of future studies. The main results are (a) an estimate of
the proportion of pregnant smokers who enrol in the scheme; (b) estimates of the proportion of pregnant smokers
who participate in the scheme and who achieve prolonged abstinence at: i. delivery and ii. six months postpartum;
(c) predictors of i. participation in the scheme, and ii. smoking cessation; and (d) estimates of the adverse effects of
using incentives to achieve quitting as indexed by: i. the delay in quitting smoking to enrol in an incentive scheme
and, ii. false reporting of smoking status, either to gain entry into the scheme or to gain an incentive.
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Background
Smoking in pregnancy
Smoking during pregnancy and in the postnatal period
harms the baby and mother. It is a major determinant of
low birth weight and a range of adverse infant health
outcomes including death [1]. Smoking in pregnancy is
heavily patterned by social and material deprivation as
well as age. In the United Kingdom of Great Britain and
Northern Ireland (UK), women in routine and manual
occupations are five times more likely than those in
managerial and professional occupations to have smoked
throughout pregnancy (20% vs. 4%, respectively), and
35% of pregnant women aged 20 years or younger
smoked throughout pregnancy, compared with 6% of
women aged 35 years and older [2]. In the US, women
with fewer than 12 years education are almost four times
more likely than women with more than 12 years educa-
tion to smoke in the last three months of pregnancy
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(22.5% vs. 6.5%, respectively), with 18.5% of women aged
under 20 years smoking in the last three months of
pregnancy compared with 7% of those aged over 35 years
[3]. These patterns of smoking contribute not only to
the health inequalities associated with adult smoking but
also to those in infancy following exposure to cigarette
smoke before and after birth.
Smoking cessation interventions in pregnant women
The UK has a strong tobacco control climate so cessa-
tion in pregnancy might be expected to be as high in the
UK as anywhere [4]. In 2010, 26% of women in the UK
smoked immediately before or during their pregnancy,
with around 54% of these stopping before delivery. It is
estimated that 12% [2] or 13% [5] of women smoke
throughout pregnancy in the UK. Similar rates are
reported in the United States of America (USA), with
12.8% of women estimated to smoke in the last three
months of pregnancy, ranging from 5.1% in Utah to
28.7% in West Virginia [3]. The National Health Service
(NHS) in the UK offers a free smoking cessation service
to all those who want to stop smoking and promotes
this to smokers. NHS support concentrates on helping
women who are still smoking by the time they book for
pregnancy care, usually around eight to 12 weeks of ges-
tation. Such support typically includes approximately
seven individual support sessions held in a nearby clinic
over a four week period plus nicotine replacement therap-
ies. This support has been shown to double cessation
rates, but only 17% of all women smoking at booking take
up the offer of support [6]. 46% of these women stop in
the short-term [6], but the NHS does not record the
proportion that stay abstinent throughout pregnancy.
Although some women may attempt to quit smoking
and stay quit prior to and during pregnancy, relapse
rates in the first 6 months after delivery are estimated at
70% [7]. Post-natal smoking and the exposure of chil-
dren to environmental tobacco smoke has been linked
with sudden infant death syndrome, respiratory diseases
and ear infections [8]. A review of current interventions
targeting relapse prevention in the post-partum period
found them ineffective and recommended the evalu-
ation of the use of financial incentives as an intervention
strategy for maintaining abstinence during this time [9].
To improve long-term smoking cessation in pregnant
women interventions are needed that both increase
referrals to smoking services and improve long-term quit
rates particularly for the vast majority of pregnant
women who do not use these services.
In a recent Cochrane review on the effectiveness of
smoking cessation interventions in pregnancy, financial
incentives were found to be the single most effective
intervention [10]. A further meta-analysis of the three
most robust trials confirmed this, with women offered
financial incentives having a greater chance of quitting
[11]. These three trials were conducted in the USA and
included only 350 women in total, leading the authors of
this latter meta-analysis to recommend replication else-
where in more robust designs using larger samples and
standardised assessments of continuous abstinence.
While showing large effect sizes, the majority of women
still fail to quit in these incentive schemes [12-14]. It is
therefore instructive to consider the individual character-
istics of those who succeed and those who fail as a basis
for strengthening future schemes. One predictor of smok-
ing cessation in pregnancy is time orientation [15]. Given
a choice, people often prefer to receive smaller, more im-
mediate rewards over larger, later ones [16]. This prefer-
ence is termed delay discounting. The more people are
willing to forego in order to reduce the delay for receiving
a reward, the higher their delay discounting. Higher delay
discounting is associated with a number of demographic
characteristics including younger age, lower education
and lower income [17]. Delay discounting may interact
with incentive schemes to predict outcomes such that
programmes offering frequent immediate rewards, as
opposed to larger less frequent ones, may be particu-
larly effective for those who discount more steeply. In
one small study, the extent to which women discounted
the future for themselves predicted quitting during
pregnancy, with women who sustained a quit attempt
beyond pregnancy discounting the future less than
those who relapsed to smoking [15]. In pregnancy
women may also discount the future for their babies as
well as for themselves given that health decisions that a
woman makes in pregnancy will affect both herself and
her baby. However, it is unknown how pregnant women
discount the future for themselves relative to that of
their future children and whether these decisions differ-
entially predict smoking cessation. This will be assessed
in the current study.
Unintended perverse effects of incentive schemes
There are at least two possible unintended perverse
effects of incentivising smoking cessation. First, it may
lead people to delay initiating a quit attempt if there is a
time interval between people being informed of a
scheme and their enrolment onto it. This is a particular
concern in pregnancy when incentive schemes may not
operate until booking for maternity care, which happens
near the end of the first trimester when the majority of
fetal development has already occurred. No previous
study has examined this. Second, incentive schemes may
encourage “gaming”, that is, people cheating a system to
receive an incentive. This may occur by non-smokers
falsely reporting themselves to be smokers to get onto a
scheme and, amongst those on a scheme, smokers falsely
reporting themselves to be non-smokers.
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Few studies have investigated the precise nature or
prevalence of these types of gaming. A recent review
examining the use of incentives in smoking cessation
studies reports limited and mixed evidence for gaming
[18]. One study included in the review reported a
greater discrepancy between self-reported abstinence
and carbon monoxide (CO) levels for participants who
were incentivized for self-reported abstinence compared
to those incentivised for low CO levels. This suggests
that gaming may be more likely if the incentive is not
contingent on biochemical verification [19]. Another
study reported that those incentivised for smoking
cessation were more likely to be classified as abstinent
(38%) as assessed by CO levels, compared with those
not incentivized (5%), a difference that disappeared
when cotinine, a more stringent test, was used to verify
abstinence (7% vs. 2%, incentivised group and control
group respectively) [20]. The results of this study
suggest that failure to include cotinine measurement to
verify abstinence will overestimate the effectiveness of
financial incentives in achieving sustained quitting.
More evidence regarding the nature and scale of gaming
in the context of incentivizing smoking cessation is
needed. In addition to informing the interpretation of
incentive scheme evaluations, estimating the nature and
scale of gaming in the proposed study will inform the
design of incentive schemes and their evaluation.
Current UK incentive schemes
An internet search [conducted on Monday 19th November
2012, see Table 1] revealed two active UK-based schemes
(one delivered as part of a routine service, and one deliv-
ered as part of a randomised controlled trial) and four
recent but currently inactive UK-based schemes in which
pregnant women are offered financial incentives. The
incentives comprised generic shopping vouchers (n = 3),
grocery vouchers (n = 1) and pharmacy vouchers (n = 1).
None offered cash. The value of the vouchers ranged from
£10 to £20 for each negative test result for smoking, based
on carbon monoxide readings. The schemes varied in the
frequency with which tests were conducted, the total
amount on offer (ranging from £100 to £650), and
duration, ranging from the end of pregnancy to a year
after enrolment.
From information available on websites and from our
knowledge of financial incentives schemes currently run-
ning in the UK, only one is part of a randomised trial
(the Cessation in Pregnancy and Incentives Trial [21]).
The current study differs from this trial by using a more
frequent incentive schedule (a maximum of 32 incentive
points compared with four), offered for longer (up to six
months postpartum compared with 36 weeks gestation),
and in which the size of incentives is incremental, as op-
posed to fixed. The incentive schedule for the current
study (see Table 2) is based on those used in two USA
studies which reported large effect sizes [13,14].
Public attitudes
The use of financial incentives attracts controversy. A
recent analysis of media coverage revealed that most
articles covered a mix of views [22]. Preliminary results
from a series of ongoing experiments reveal that the
majority of participants were prepared to trade-off their
negative attitudes towards financial incentives against
increased effectiveness, i.e. the more effective a scheme,
the more acceptable it is judged to be [23].
We describe here a single arm intervention study to be
conducted within NHS Derbyshire County at the Chester-
field Royal Hospital NHS Foundation Trust. Between
April 2010 to March 2011, 2881 women received care at
Chesterfield Royal Hospital NHS Foundation Trust at de-
livery, out of which a similar proportion smoked at book-
ing (Women smoking at booking n = 500, 17% of total
women booking) as they did at delivery (Women smoking
at delivery n = 483, 17% of total women delivering). The
current study will describe smoking cessation rates in all
smokers receiving antenatal care from midwives based at
one hospital, Chesterfield Royal Hospital NHS Foundation
Trust, for a 12 month period. During this period all preg-
nant women who smoke will be offered participation in a
financial incentive scheme for smoking cessation, regard-
less of whether they are interested in stopping smoking or
planning to use stop smoking services. The current study
can therefore be characterized as a “cessation induction”
study, as distinct from an “aid to cessation” study, mean-
ing that it aims to encourage women who would not have
tried to quit smoking to do so.
Study aim and objectives
The aim of this study is to assess the potential effectiveness
of using financial incentives to achieve smoking cessation
in pregnant women who smoke, to inform the use of
financial incentive schemes in routine clinical practice
as well as the interpretation of existing trials and the
design of future studies.
The specific objectives of the study are:
1) To estimate the proportion of pregnant women who
smoke at the point of receiving antenatal care from
midwives, at one hospital over a 12 month period,
who accept the offer to participate in a financial
incentive scheme for smoking cessation
2) To estimate the proportion of pregnant women who
smoke, and who participate in the scheme and
achieve prolonged abstinence at (a) delivery and
(b) six months post-partum
3) To examine predictors of (a) participation in the
scheme, and (b) smoking cessation
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4) To estimate the prevalence of two possible sets of
adverse effects of using incentives to achieve
quitting:
a) Delay in quitting, in order to enrol in an
incentive scheme
b) Gaming i.e. false reporting of smoking status:
i) to gain entry to the scheme (i.e. non-smokers
acting as smokers)
ii) to gain an incentive (i.e. smokers acting as
non-smokers)
5) To describe the process of visits for incentive
payment assessments both in patients’ homes and in
clinic settings. This will include the total number of
visits, the length of each visit, visits defaulted,
mileage travelled and total time taken.
Methods/Design
The study has been approved by the Derbyshire Re-
search Ethics committee [Ref no.11/H0401/2].
Overview of design
This is a single arm intervention study in which preg-
nant smokers attending for antenatal care are offered
participation in a financial incentive scheme for smoking
cessation.
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The incentive scheme
Pregnant women participating in the scheme will be
asked to provide verification of smoking cessation on
up to 32 occasions, depending on when they enrol (see
Table 2). Women must declare complete abstinence
since last contact, validated by a “test-negative” exhaled
carbon monoxide (CO) measurement, i.e. a concentra-
tion of less than or equal to 6 ppm. At each visit when
cessation is reported and validated, participants will
receive a voucher for shopping items. The value of the
voucher received at the first visit will be £8, increasing
by £1 at each consecutive visit at which smoking cessa-
tion is reported and validated using CO measurement.
The scheme has the following four characteristics:
Type: the incentive offered is a voucher card which can
be topped-up and used to redeem a range of goods
including groceries, clothes, baby and other consumer
goods. It cannot be used in exchange for cigarettes or
alcohol.
Magnitude: the total amounts offered are £248 for
abstinence during pregnancy and £504 for abstinence
six months post partum. These are similar to the
amounts offered in the three randomised controlled
trials conducted in the US, each of which reported
large effects on abstinence [12-14]. The whole sum is
available only to women who sustain abstinence and
verify this biochemically for the entire duration of this
period.
Duration: each participant in the incentive scheme can
be enrolled for around a year, to maximise abstinence
during pregnancy and in the first six months post-
partum.
Frequency: incentives are offered more frequently
during the first two weeks of quit attempts to
maximise quitting in this time period, which is a major
predictor of ultimate success [24]. Increasing the
amount that can be earned with abstinence is shown in
laboratory studies to be more effective than offering
constant or decreasing amounts [25]. Once a
behaviour is established, reducing the frequency of
rewards is important in maintaining the change [26].
Our proposed incentive structure reflects these three
sets of observations (Table 2). Two of the three US
trials used this structure [13,14]. None of the UK pilot
schemes of which we are aware has used this
structure.
The incentive scheme ‘starts again’ after birth for two
reasons. First, women who have smoked during pregnancy
may now wish to become abstinent to avoid affecting their
child’s health through environmental tobacco smoke and/
or breast milk. For them, this incentive frequency mir-
rors that during pregnancy for the initial days of a quit
attempt. Second, we know that return to smoking after
pregnancy is a deliberate choice by many mothers when
the incentive to be abstinent due to carrying a baby
attached by a placenta is removed. The incentive struc-
ture is designed to reward a woman frequently during
the initial postpartum period to maintain the incentive
to be abstinent when the natural incentive to do so
has gone.
Table 2 Incentive schedule 1
Visit no. Visit timepoint Incentive (£) Cumulative total (£)
1 1 day after quitting 8 8
2 3 days after quitting 8 + 1 17
3 7 days after quitting 9 + 1 27
4 12 days after quitting 10 + 1 38
5 3 weeks after quitting 11 + 1 50
6 4 weeks after quitting 12 + 1 63
7 5 weeks after quitting 13 + 1 77
8 6 weeks after quitting 14 + 1 92
9 8 weeks after quitting 15 + 1 108
10 10 weeks after quitting 16 + 1 125
11 12 weeks after quitting 17 + 1 143
12 14 weeks after quitting 18 + 1 162
13 16 weeks after quitting 19 + 1 182
14 20 weeks after quitting 20 + 1 203
15 24 weeks after quitting 21 + 1 225
16 28 weeks after quitting 22 + 1 248
DELIVERY
17 2 day after delivery 23 + 1 272
18 4 days after delivery 24 + 1 297
19 7 days after delivery 25 + 1 323
20 12 days after delivery 26 + 1 350
21 3 weeks after delivery 27 + 1 378
22 4 weeks after delivery 28 + 1 407
23 5 weeks after delivery 29 + 1 437
24 6 weeks after delivery 30 + 1 468
25 8 weeks after delivery 31 + 1 500
26 10 weeks after delivery 32 + 1 533
27 12 weeks after delivery 33 + 1 567
28 14 weeks after delivery 34 + 1 602
29 16 weeks after delivery 35 + 1 638
30 20 weeks after delivery 36 + 1 675
31 24 weeks after delivery 37 + 1 713
32 28 weeks after delivery 38 + 1 752
1 This table shows the maximum that can be earned by a woman who starts
on the scheme at about 12 weeks gestation and who attends all scheduled
visits and is verified as not smoking at each visit. A woman starting quitting
later in pregnancy would start with Visit 1 in terms of the incentive on offer. If
she delivered shortly after Visit 12, her post delivery visit is paid at the rate of
Visit 13. The maximum number of visits this woman could make is 28.
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Measuring smoking cessation
To assess the effectiveness of the intervention it is
necessary to have an accurate measure of smoking
cessation. For most people who smoke cigarettes and
have difficulty quitting (addicted smokers), only the
state of complete abstinence is sustainable as occasional
smoking leads to reinstatement of fulltime smoking.
The outcome of choice for smoking cessation studies
should therefore be prolonged or continuous abstinence
[27,28]. In particular, this is the only outcome known to
be associated with health benefits.
Biochemical verification tests, such as testing CO
levels or nicotine metabolites such as cotinine, are the
preferred methods of validating smoking cessation in
clinical studies such as this [29]. Testing for CO levels
using a breath test assesses smoking in the preceding
one to four hours whereas cotinine analysis from blood,
urine or saliva samples can measure exposure to smok-
ing in the preceding few days [29]. However, testing for
cotinine in body fluids is more complex to administer
and expensive to analyse than testing CO levels.
In the current study we will use cotinine from urine
samples to confirm smoking status at recruitment, and
from saliva samples to verify abstinence both at delivery
and at six months post-partum. Cotinine testing will also
be used once during pregnancy (at around 28 weeks) to
compare with CO measurements taken at the same time.
For practical reasons, CO tests alone will be used on all
other occasions when women attend to receive incentive
payments.
Study outcomes
Smoking cessation: assessed on two occasions
Self-reported, prolonged complete abstinence from smok-
ing (a) between six weeks after enrolment in the scheme
and prior to childbirth; and (b) between childbirth and six
months later. All women lost to follow-up will be assumed
to have resumed smoking. This definition gives women a
cessation induction period of up to six weeks, although we
expect many women will establish abstinence sooner than
this.
These are two outcomes requiring the following different
measures:
(a)between six weeks after enrolment in the scheme
and prior to childbirth
i. self reported smoking cessation for at least
24 hours at six weeks after enrolment in the
scheme, validated by exhaled CO measurement of
less than or equal to 6 ppm;
ii. self reported complete abstinence from 6 weeks
after enrolment to 36 weeks gestation, validated
by salivary cotinine less than 15 ng/ml at
36 weeks. In addition, there must be no reported
lapses and a record that all CO readings taken
between these dates indicate non-smoking status.
All women lost to follow-up will be assumed to
have resumed smoking.
(b)between childbirth and six months later
i. self reported smoking cessation for at least
24 hours two days after delivery, validated by
exhaled CO measurement of less than or equal to
6 ppm and salivary cotinine less than 15 ng/ml, in
keeping with local practice.
ii. self reported complete abstinence from two days
after enrolment to six months postpartum,
validated by salivary cotinine less than 15 ng/ml
at six months. In addition, there must be no
reported lapses and a record that all CO
readings taken between these dates indicate
non-smoking status [27]. All women lost to
follow-up will be assumed to have resumed
smoking.
Other measures of smoking status Self reported
prolonged abstinence from smoking assessed by self-
reported smoking cessation six weeks after enrolment in
the scheme, validated by CO reading, and self report
smoking cessation at 28 weeks gestation, validated by
salivary cotinine less than 15 ng/ml.
Participation in the scheme This will be recorded by
the study support worker and presented as a proportion
of all women routinely recorded at booking consulta-
tions as smoking.
Predictors of smoking cessation Women will complete
a questionnaire when they are recruited to the scheme
to assess the following: delay discounting for self and the
baby, using an adapted version of Kirby and Marakovic’s
task [16]; nicotine addiction, using the Fagerstrom test
for nicotine dependence [30]; and, socio-economic sta-
tus, assessed using postcode as an index of area level
deprivation.
Estimating the adverse effects of using incentives to achieve
quitting
a) delay in quitting smoking to enrol in an incentive
scheme: There are concerns that the estimated 11%
of women who quit smoking upon learning they
are pregnant may delay quitting until they can
enrol in the incentive scheme. We will estimate
this effect by comparing the self-reported smoking
status of women during the time the scheme is
running, with that recorded for the preceding
12 months. While this is open to the usual biases
associated with historic controls, it will provide
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some indication of whether the scheme has
delayed quitting.
b) gaming i.e. false reporting of smoking status: Two
types of gaming are possible;
i) To gain entry to the scheme (i.e. non-smokers
acting as smokers). We will estimate this in two
ways: first, using historic controls (by comparing
the proportion of women who claim to smoke at
the outset of the study with the proportion who
reported being smokers in the year prior to the
start of the scheme); second, by assessing the
proportion of women claiming to smoke with
levels of urinary cotinine compatible with non-
smoker status. Our inclusion criteria are set to
minimise entry to the scheme by non-smokers.
ii) To gain an incentive (i.e. smokers acting as non-
smokers). We will estimate this by validating CO
records and self-reported smoking status against
measurement of cotinine collected at 28 weeks
gestation, 36 weeks gestation and 2 days after
delivery and 6 months post-partum.
The two primary outcomes of this study are:
 smoking cessation at delivery; and,
 false reporting of smoking status to gain an
incentive.
The remaining outcomes will be considered secondary.
Fidelity to protocol
Fidelity to protocol checks will comprise checking recorded
CO measurements against incentives paid, and dates on
which visits were scheduled and dates on which these
occurred.
Barriers and facilitators
Two interviews will be conducted via telephone with all
women recruited to the scheme six weeks after recruit-
ment and four weeks after their participation in the
scheme ends. The aims of these interviews are to explore
barriers and facilitators to success.
Participant selection and withdrawal
All women reporting smoking and who are booked for
antenatal care by midwives employed by Chesterfield
Royal Hospital NHS Foundation Trust, over a 12 month
period, will be informed about the scheme regardless of
where they choose to deliver.
Inclusion criteria
Eligible pregnant women are those who meet the follow-
ing smoking criteria:
▪ Pregnant women who self report as smokers
▪ Pregnant women who have a urinary cotinine
concentration of 1.5 mg/ml or above
Exclusion criteria
▪ Women who are unable to provide informed
consent.
▪ Women who are under 16.
▪ Women who do not speak English.
Women who drop out from the scheme will be counted
as smokers in any analysis unless they have died or moved
to an untraceable address in which case they will be
excluded from the numerator and the denominator, in line
with Russell standard criteria for reporting smoking cessa-
tion outcomes from studies [27].
Women who miscarry or have a stillbirth will be allowed
to continue in the scheme if they so choose. They will,
however, be excluded from the numerator and denomin-
ator of the cessation rate, in line with Russell standard
criteria [27]. For these women the date of miscarriage
or stillbirth will be classed as the date of delivery and
the incentive schedule adjusted accordingly.
Recruitment and screening
Midwives currently record the smoking status of all
women they book for antenatal care. All women reporting
to a midwife at booking that they smoke occasionally or
every day will be referred to the Derbyshire Community
Healthcare Service (DCHS) Stop Smoking Service (SSS) as
is current standard care. Forms describing the smoking
status of all women being booked during the pilot period
will be posted first class to the SSS. The midwife will give
women who smoke two leaflets: one that outlines the
incentive scheme and one outlining the stop smoking
services.
Women who smoke will be phoned by a support
worker from the SSS within one working day of receipt
of their referral from the midwife. The support on offer
will be described, namely stop smoking services and the
financial incentive scheme. Women will be informed
that the latter is for heavier smokers with joining
dependent upon a urinary cotinine concentration above
a certain level (at least 1.5 mg/ml).
Enrolment
Women wanting to be considered for the scheme will be
posted the participant information sheet and a home
visit with the support worker will be arranged. At this
enrolment visit a urine sample will be tested to confirm
eligibility for the scheme, using a point of care test. (See
Figure 1 for recruitment process).
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All women will be offered the standard support by the
SSS regardless of whether they take part in the financial
incentive scheme.
Pregnant women who meet the inclusion criteria will
be enrolled into the study. Provided they have read and
understood the participant information sheet and had
the chance to have any questions answered, signed con-
sent will be sought for the following:
(a)participation in the scheme;
(b)collection and analysis of one urine and four saliva
samples for cotinine estimation: two during
pregnancy (28 and 36 weeks gestation) and two
post-partum (two days after delivery, and six months
post-partum);
(c)completion of a questionnaire to assess predictors of
smoking cessation.
Once consent has been given, the support worker will
encourage the participant to set a quit date and issue
them with a ‘programme passport’ which will contain
their photograph for identification and the date, test re-
sult and voucher value of each visit.
Starting a quit attempt
After this visit, once a woman has set a quit date, she
contacts the support worker by phone to arrange for the
support worker to visit her at home, within 24 hours.
Visits
These visits are conducted by the support worker who
records all visits manually on client record cards; this
information is subsequently entered into the study
database.
During pregnancy, CO tests will take place on up to
16 occasions (depending upon when in pregnancy
women enrol in the scheme), most frequently in the
first two weeks (4 occasions) with decreasing frequency
until delivery. After delivery and until 6 months post-
partum, testing will also take place on 16 occasions;
with decreasing frequency (Table 2). If participants are
not available on the scheduled visit date or the date falls
Programme Delivery 
Woman self-reports as a smoker and the CO test 
shows green, amber or red reading 
OR
Woman self-reports as a non-smoker but the CO 
test gives an amber or red reading 
The midwife informs the woman of the financial 
incentive scheme and that she will be contacted 
by the stop smoking service (SSS).  
If the urine sample has a 
test result of at least 
1.5mg/ml, informed 
consent is obtained and 
the woman is given a 
‘programme passport’ 
with her visit schedule. 
If the urine sample 
has a test result of 
less than 1.5mg/ml 
a woman is not 
enrolled onto the 
scheme.  
A midwife assesses a woman’s smoking status, 
at the booking appointment, using self-report and 
the CO test.  
If a woman declines, 
midwives mark that 
she has opted out and 
she is not contacted 
about the financial 
incentive scheme.  
If a woman agrees, her 
details are sent to the SSS 
If a woman is not 
interested in the 
scheme she is not 
enrolled and not 
contacted again.  Enrolment Visit: A urine sample is obtained. 
If a woman is interested in the incentive scheme 
an enrolment visit is set up with the support worker.  
The SSS support worker contacts all women 
referred to ascertain interest in taking part in the 
scheme and offers them standard stop smoking 
support.  
Figure 1 Flow of recruitment process.
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on a weekend, the visit will be rescheduled for one
working day before or after the scheduled date for the
first 1–4 visits and two working days for the following
visits.
At the first visit participants are given a voucher card
and receive £8 on it for a negative CO test. The sum
given at each visit increases by an increment of £1 for
every successive negative CO test.
Failure to attend for a scheduled visit or testing posi-
tive for smoking means no incentive is given at that visit
and the incentive value is reset to the baseline of £8 at
the next successful visit. Following two consecutive suc-
cessful test results, the incentive value is re-set to the
highest point attained prior to the positive for smoking
test result.
Women can continue in the scheme for as long as
they choose but incentives are only provided to those
stopping smoking.
CO testing is undertaken in a woman’s home for the
first four weeks and thereafter women are required to at-
tend one of five drop-in clinics held in the local commu-
nity. If a participant cannot get to a drop-in session for a
visit due to illness or the visit is too close to delivery, the
support worker visits the woman at home.
At each visit, whether at a home or at a community
clinic, the support worker does the following:
1. checks and records smoking status: self report and
CO measurement
2. if the woman reports she is not smoking, and her
CO reading is ≤6 ppm, then:
a. voucher payment is approved
b. the results, date of the next visit and the value of
the next incentive payment are recorded in the
woman’s hand held notes.
3. if the woman reports she is smoking or her CO
reading is ≥6 ppm, then
a. voucher payment is not approved
b. the procedure for the next visit is discussed
c. the results, date of next visit and the value of the
next incentive payment (£8) is recorded in her
hand held notes.
4. the support worker answers any questions and
provides general encouragement; women wanting
smoking cessation advice are encouraged to use the
NHS stop smoking service.
The duration of each visit is between ten and 25 minutes.
Missed visits
If a woman is not at home when a scheduled visit was
arranged, the support worker calls the woman from the
latter’s doorstep. If no response is obtained, a prepared
note is left at the woman’s home requesting she contacts
the support worker in the next 48 hours. If no contact is
made, the support worker contacts the woman. A similar
procedure is followed for women who do not attend an
appointment scheduled in the community, with follow
up letters posted, rather than being left at her home.
Biological samples taken to assess quitting and gaming
A urine sample is tested at the enrolment visit, using a
dipstick test, to assess eligibility for the scheme, with
urinary cotinine concentrations equal to or more than
1.5 mg/ml sufficient for enrolment.
Saliva samples are collected by the support worker at
28 weeks gestation, 36 weeks gestation, 2 days post
delivery and amongst women reporting cessation, at
6 months post delivery and analysed by a nationally
accredited laboratory for cotinine concentrations. For
women reporting current use of nicotine replacement
therapy, anabasine, a tobacco specific alkaloid, will be
analysed.
In addition to being used to biochemically verify quit-
ting, the results of these analyses will be used to estimate
the proportions of women reporting having quit who
have not. Both women and the support worker will re-
main blinded to the test results unless a woman requests
her result. Women proven to be smoking on any of
these extra tests (i.e. those using saliva as opposed to
CO) will not be confronted with this, withdrawn from
the scheme or refused vouchers. The aim is to estimate
the extent of the gaming that is occurring. It is possible
for women to abstain for a few hours and pass a CO test
but such women would be shown to be smokers by
salivary cotinine.
Post-recruitment retention
Women enrolled in the scheme who do not keep pre-
arranged meetings to report their smoking status as per
the scheme protocol are contacted by telephone by a
support worker. Failure to respond after three attempts
at contact is assumed to signal withdrawal from the
scheme.
Data collection and management
Data on women’s progress through the scheme are col-
lected by the support workers and entered onto a data
base by a member of the evaluation team. Data on bio-
chemical tests are entered by the evaluation team with
the support worker remaining blinded to these results.
Economic evaluation
No formal economic evaluation is planned for this study.
The total budget set aside over two years for the scheme
by the Primary Care Trust is £139,000. These costs cover
the employment of 1.5 support workers (paid on a pay
scale in the range £16,110-£19,077), the costs of the
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incentives and the laboratory costs for saliva testing.
This money does not cover the costs of NHS Stop
Smoking Advisors who women access through the
existing scheme.
Precision estimation
This is a single arm intervention study that aims to es-
timate the proportions of women who join the scheme
and who achieve prolonged abstinence, as well as the
proportion of women who falsify smoking status to
gain rewards. We will offer the scheme for 12 months
which will likely involve a group of an estimated 500
pregnant women based upon the number of smokers
booking for care at Chesterfield Royal Hospital NHS
Foundation Trust in the preceding 12 month period.
We estimate that about 30% of smokers approached
will enrol, based on 45% recruitment rate in a “cessation
induction” trial of incentives that used similar eligibility
criteria, conducted in the US [14], and estimated 14%
and 10% recruitment rates to two recent UK “aid to ces-
sation” trials for pregnant women trying to quit smok-
ing and not involving any financial incentives [31,32]. A
population of 500 will provide an estimate in the region
of 30% recruitment with a precision of +/− 4%, using
95% confidence intervals. Estimating 24% quit rates in
the 150 enrolled women, based on estimates generated
in a recent systematic review [10] will provide an esti-
mate with a precision of +/− 7%, using 95% confidence
intervals. We conservatively estimate that the propor-
tion of women quitting will be larger than zero, the rate
observed for the preceding period of observation in the
study hospital. All women lost to follow-up will be
assumed to have resumed to smoking. It is planned to
recruit all smokers, regardless of motivation to stop
smoking.
Data analysis
Outcomes will be reported as proportions with 95%
confidence intervals for the following: (a) the propor-
tion of pregnant smokers who enrol in the scheme;
(b) the proportion of pregnant smokers who partici-
pate in the scheme and who achieve prolonged abstin-
ence at i. delivery and ii. six months postpartum; and,
(c) the proportion of women who falsely report smok-
ing status to gain entry into the scheme and to gain an
incentive. No formal statistical tests will be performed.
Rates of prolonged abstinence will be considered to
suggest a positive impact of the scheme if the 95%
confidence intervals do not include 0%. This is the rate
of cessation recorded in a similar population of women
in the preceding 12 months in the hospital where the
study is taking place.
Reporting of study results
The results of this study will be submitted for publica-
tion in a peer reviewed journal in December 2013, three
months after the last data point will have been collected.
Discussion
Two aspects of the design of this study limit the inferences
that can be made regarding the impact of the incentive
scheme on quitting. First, the study does not include a
comparison group that receives no intervention. Second,
the intervention can be considered a complex behavioural
intervention involving not only the provision of incentives
but support that is additional to standard care, a limitation
that is evident in most, if not all, studies of incentive
schemes [33]. The study will nonetheless provide esti-
mates of the participation and drop-out rates for the
scheme and an indication of possible effect size. It will also
provide rigorous data on “gaming” in incentive schemes,
in a way that no other study has so far done. These latter
data have implications for the interpretation of previous
studies as well as the design of subsequent studies using
financial incentive to motivate smoking cessation.
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